home / stock / lyel / lyel quote
Last: | $2.78 |
---|---|
Change Percent: | 0.0% |
Open: | $2.61 |
Close: | $2.78 |
High: | $2.8 |
Low: | $2.55 |
Volume: | 647,926 |
Last Trade Date Time: | 05/16/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.78 | $2.61 | $2.78 | $2.8 | $2.55 | 647,926 | 05-16-2024 |
$2.61 | $2.63 | $2.61 | $2.72 | $2.5 | 493,040 | 05-15-2024 |
$2.54 | $2.49 | $2.54 | $2.6 | $2.415 | 434,923 | 05-14-2024 |
$2.4 | $2.46 | $2.4 | $2.52 | $2.395 | 591,478 | 05-13-2024 |
$2.46 | $2.56 | $2.46 | $2.715 | $2.445 | 651,252 | 05-10-2024 |
$2.68 | $2.52 | $2.68 | $2.7 | $2.495 | 1,031,052 | 05-09-2024 |
$2.5 | $2.55 | $2.5 | $2.58 | $2.47 | 839,769 | 05-08-2024 |
$2.54 | $2.46 | $2.54 | $2.55 | $2.42 | 926,958 | 05-07-2024 |
$2.54 | $2.34 | $2.54 | $2.54 | $2.34 | 834,517 | 05-06-2024 |
$2.36 | $2.44 | $2.36 | $2.66 | $2.35 | 446,610 | 05-03-2024 |
$2.4 | $2.38 | $2.4 | $2.44 | $2.315 | 799,681 | 05-02-2024 |
$2.33 | $2.18 | $2.33 | $2.38 | $2.14 | 825,226 | 05-01-2024 |
$2.17 | $2.23 | $2.17 | $2.255 | $2.16 | 560,099 | 04-30-2024 |
$2.25 | $2.19 | $2.25 | $2.275 | $2.19 | 414,247 | 04-29-2024 |
$2.17 | $2.19 | $2.17 | $2.21 | $2.11 | 352,183 | 04-26-2024 |
$2.2 | $2.3 | $2.2 | $2.5292 | $2.15 | 540,834 | 04-25-2024 |
$2.3 | $2.42 | $2.3 | $2.48 | $2.29 | 775,286 | 04-24-2024 |
$2.44 | $2.36 | $2.44 | $2.55 | $2.36 | 687,208 | 04-23-2024 |
$2.41 | $2.2 | $2.41 | $2.42 | $2.1912 | 958,851 | 04-22-2024 |
$2.23 | $2.31 | $2.23 | $2.38 | $2.15 | 1,080,193 | 04-19-2024 |
News, Short Squeeze, Breakout and More Instantly...
Lyell Immunopharma Inc. Company Name:
LYEL Stock Symbol:
NASDAQ Market:
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical?stage T-cell reprogramming co...
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team wil...
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarter On track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced TIL product candidate, in the secon...